| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial V Heinemann, LF von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, ... The lancet oncology 15 (10), 1065-1075, 2014 | 1966 | 2014 |
| Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced … SE Al-Batran, N Homann, C Pauligk, TO Goetze, J Meiler, S Kasper, ... The Lancet 393 (10184), 1948-1957, 2019 | 1933 | 2019 |
| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Jama 307 (12), 1265-1272, 2012 | 1156 | 2012 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1136 | 2018 |
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft … SE Al-Batran, JT Hartmann, S Probst, H Schmalenberg, S Hollerbach, ... Journal of clinical oncology 26 (9), 1435-1442, 2008 | 960 | 2008 |
| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of Clinical Oncology 38 (1), 11, 2020 | 785 | 2020 |
| Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients … SE Al-Batran, RD Hofheinz, C Pauligk, HG Kopp, GM Haag, KB Luley, ... The lancet oncology 17 (12), 1697-1708, 2016 | 711 | 2016 |
| Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma MJ Rummel, SE Al-Batran, SZ Kim, M Welslau, R Hecker, ... Journal of Clinical Oncology 23 (15), 3383-3389, 2005 | 564 | 2005 |
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study A Ohtsu, JA Ajani, YX Bai, YJ Bang, HC Chung, HM Pan, T Sahmoud, ... Journal of Clinical Oncology 31 (31), 3935, 2013 | 547 | 2013 |
| Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction … YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz, M Schenker, ... Annals of Oncology 29 (10), 2052-2060, 2018 | 480 | 2018 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of … S Stintzing, DP Modest, L Rossius, MM Lerch, LF von Weikersthal, ... The Lancet Oncology 17 (10), 1426-1434, 2016 | 455 | 2016 |
| Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial SE Al-Batran, N Homann, C Pauligk, G Illerhaus, UM Martens, ... JAMA oncology 3 (9), 1237-1244, 2017 | 395 | 2017 |
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis YY Janjigian, D Werner, C Pauligk, K Steinmetz, DP Kelsen, E Jäger, ... Annals of oncology 23 (10), 2656-2662, 2012 | 378 | 2012 |
| Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer RD Hofheinz, SE Al-Batran, F Hartmann, G Hartung, D Jäger, C Renner, ... Oncology Research and Treatment 26 (1), 44-48, 2003 | 371 | 2003 |
| Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised … DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, ... The lancet oncology 18 (11), 1467-1482, 2017 | 325 | 2017 |
| Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for … SE Al-Batran, N Homann, H Schmalenberg, HG Kopp, GM Haag, ... Journal of Clinical Oncology 35 (15_suppl), 4004-4004, 2017 | 317 | 2017 |
| Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer SE Al-Batran, A Atmaca, S Hegewisch-Becker, D Jaeger, S Hahnfeld, ... Journal of clinical oncology 22 (4), 658-663, 2004 | 309 | 2004 |
| German S3-guideline" Diagnosis and treatment of esophagogastric cancer" M Moehler, SE Al-Batran, T Andus, M Anthuber, J Arends, D Arnold, ... Zeitschrift fur Gastroenterologie 49 (4), 461-531, 2011 | 304 | 2011 |
| Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of … SE Al-Batran, JT Hartmann, R Hofheinz, N Homann, V Rethwisch, ... Annals of Oncology 19 (11), 1882-1887, 2008 | 301 | 2008 |
| Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non … S Hegewisch-Becker, U Graeven, CA Lerchenmüller, B Killing, ... The Lancet Oncology 16 (13), 1355-1369, 2015 | 280 | 2015 |
